Phase 2 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with stage IV colorectal cancer
- People whose cancer can be measured on scans using a standard set of medical measurement rules called RECIST 1.1
- People who are planning to start a first-line chemotherapy regimen based on a drug called 5-fluorouracil (5FU) for colon cancer, with the specific regimen chosen by their treating doctor
- People who previously received chemotherapy after surgery (adjuvant therapy), as long as it was completed more than 6 months ago
- People with a general health and activity level rated 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities)
- People whose blood test results meet minimum levels for white blood cells, platelets, and haemoglobin (red blood cells), including if those levels were reached with a transfusion or other support
- People whose liver enzyme levels (AST and ALT) fall within acceptable ranges — higher limits apply for those with known liver metastases (confirm with trial site)
- People whose kidney function meets a minimum threshold, based on a blood test or a calculation using age, weight, and sex
- People who are not pregnant and not currently breastfeeding
- People of childbearing potential who agree to use an acceptable form of contraception throughout the study and for a period after treatment ends, as guided by their specific chemotherapy regimen
- People already taking a daily aspirin regimen before the study — this does not need to be stopped to participate
- People who have a medical reason they cannot take aspirin — participation is still possible, and aspirin would not be required as part of their study treatment
Who may not be able to join:
- People who have had their entire colon surgically removed (total colectomy)
- People who have been diagnosed with Cockayne Syndrome
- People currently taking disulfiram, tizanidine, or theophylline who are unable to stop these medications for the duration of a specific part of the study treatment
- People taking methotrexate at a dose of 15 mg per week or higher
- People who have had an allergic reaction to ciprofloxacin, metronidazole, or aspirin
- People who completed a full course of antibiotics (5 or more doses taken to treat a specific infection) in the 30 days before starting chemotherapy — note that antibiotics used for surgical prevention are allowed
- People whose heart electrical activity, measured on a baseline ECG, shows a corrected QT interval above 480 (a specific heart rhythm measurement — confirm with trial site)
- People who have been diagnosed with a condition that affects the body's ability to absorb nutrients from food (malabsorptive syndrome)
- People who are unable to swallow tablets
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Emily Kinsey, MD, Virginia Commonwealth University
Phone: 804-628-6430
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Best response by analysis using Response Evaluation Criteria in Solid Tumors
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.